Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

5274 ARTÍCULOS , VIENDO DEL 4606 AL 4620

Vitamins and Infusion of Levodopa-Carbidopa Intestinal Gel

Taher J, Naranian T, Poon YY, Merola A, Mestre T, Suchowersky O, Kulasingam V, Fasano A.

Can J Neurol Sci. 2022 Jan;49(1):19-28. doi: 10.1017/cjn.2021.78. Epub 2021 Apr 20.

Gastrointestinal dysfunction in Parkinson's disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation

Metta V, Leta V, Mrudula KR, Prashanth LK, Goyal V, Borgohain R, Chung-Faye G, Chaudhuri KR.

J Neurol. 2022 Mar;269(3):1154-1163. doi: 10.1007/s00415-021-10567-w. Epub 2021 Apr 21.

Emerging urinary alpha-synuclein and miRNA biomarkers in Parkinson's disease

Giri B, Seamon M, Banerjee A, Chauhan S, Purohit S, Morgan J, Baban B, Wakade C.

Metab Brain Dis. 2022 Aug;37(6):1687-1696. doi: 10.1007/s11011-021-00735-2. Epub 2021 Apr 21.

An umbrella review of systematic reviews and meta-analyses of observational investigations of obstructive sleep apnea and health outcomes

Chen W, Li Y, Guo L, Zhang C, Tang S.

Sleep Breath. 2022 Mar;26(1):167-188. doi: 10.1007/s11325-021-02384-2. Epub 2021 Apr 24.

Protective properties of GLP-1 and associated peptide hormones in neurodegenerative disorders

Hölscher C.

Br J Pharmacol. 2022 Feb;179(4):695-714. doi: 10.1111/bph.15508. Epub 2021 May 29.

Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor

Wei Y, Chang L, Hashimoto K.

Mol Psychiatry. 2022 Jan;27(1):559-573. doi: 10.1038/s41380-021-01121-1. Epub 2021 May 7.

Efficacy of dance for Parkinson's disease: a pooled analysis of 372 patients

Hasan SM, Alshafie S, Hasabo EA, Saleh M, Elnaiem W, Qasem A, Alzu'bi YO, Khaled A, Zaazouee MS, Ragab KM, Nourelden AZ, Doheim MF.

J Neurol. 2022 Mar;269(3):1195-1208. doi: 10.1007/s00415-021-10589-4. Epub 2021 May 8.

Sirtuins as pharmacological targets in neurodegenerative and neuropsychiatric disorders

Leite JA, Ghirotto B, Targhetta VP, de Lima J, Câmara NOS.

Br J Pharmacol. 2022 Apr;179(8):1496-1511. doi: 10.1111/bph.15570. Epub 2021 Jun 24.

A critical role for GM1 ganglioside in the pathophysiology and potential treatment of Parkinson's disease

Schneider JS.

Glycoconj J. 2022 Feb;39(1):13-26. doi: 10.1007/s10719-021-10002-2. Epub 2021 May 26.

The development of inhibitors of leucine-rich repeat kinase 2 (LRRK2) as a therapeutic strategy for Parkinson's disease: the current state of play

Azeggagh S, Berwick DC.

Br J Pharmacol. 2022 Apr;179(8):1478-1495. doi: 10.1111/bph.15575. Epub 2021 Jun 22.

Gout and Levodopa: An unknown adverse effect?

Quarteroni L, Gastaldi R, Baillet A, Moro E, Allenet B, Khouri C.

Fundam Clin Pharmacol. 2022 Feb;36(1):221-223. doi: 10.1111/fcp.12706. Epub 2021 Jun 15.

Telemedicine in Neurology: A Scoping Review of Key Outcomes in Movement Disorders

Houston E, Kennedy AG, O'Malley D, Rabinowitz T, Rose GL, Boyd J.

Telemed J E Health. 2022 Mar;28(3):295-308. doi: 10.1089/tmj.2021.0117. Epub 2021 Jun 8.

Detecting retinal cell stress and apoptosis with DARC: Progression from lab to clinic

Cordeiro MF, Hill D, Patel R, Corazza P, Maddison J, Younis S.

Prog Retin Eye Res. 2022 Jan;86:100976. doi: 10.1016/j.preteyeres.2021.100976. Epub 2021 Jun 5.

Quantifying activities of daily living impairment in Parkinson's disease using the Functional Activities Questionnaire

Becker S, Pauly C, Lawton M, Hipp G, Bowring F, Sulzer P, Hu M, Krüger R, Gasser T, Liepelt-Scarfone I.

Neurol Sci. 2022 Feb;43(2):1047-1054. doi: 10.1007/s10072-021-05365-1. Epub 2021 Jun 10.

The CXCL12/CXCR4/ACKR3 Response Axis in Chronic Neurodegenerative Disorders of the Central Nervous System: Therapeutic Target and Biomarker

Yan Y, Su J, Zhang Z.

Cell Mol Neurobiol. 2022 Oct;42(7):2147-2156. doi: 10.1007/s10571-021-01115-1. Epub 2021 Jun 12.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias